Myoclonus

Current Opinion in Neurology

Volumn 22, Issue 4, 2009, Pages 414-418

  Gerschlager, Willi ^a   Brown, Peter ^b  

^a Krankenhaus Hietzing mit Neurologischem Zentrum Rosenhugel   (Austria)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Dystonia; Epilepsy; Myoclonus; Orthostatic

Indexed keywords

ANTICONVULSIVE AGENT; CLONAZEPAM; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; LEVODOPA; METOCLOPRAMIDE; OXYBATE SODIUM; PIRACETAM; PREGABALIN; VALPROIC ACID; VIGABATRIN;

AGING; BENIGN ADULT FAMILIAL MYOCLONIC EPILEPSY; BRAIN DEPTH STIMULATION; CLINICAL FEATURE; DISEASE COURSE; DRUG EFFICACY; DYSTONIA; EPILEPSY; FOCAL MYOCLONUS; GENE MUTATION; HICCUP; HUMAN; JERKY TREMOR; JUVENILE MYOCLONIC EPILEPSY; MULTIFOCAL MYOCLONUS; MYOCLONUS; MYOCLONUS DYSTONIA; MYOCLONUS EPILEPSY; NEUROSURGERY; ORTHOSTATIC MYOCLONUS; PATHOPHYSIOLOGY; REVIEW; SEDATION; SIDE EFFECT; TERATOGENICITY; TREATMENT OUTCOME; TREMOR;

BRAIN; HUMANS; MYOCLONUS;

EID: 68449085111     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32832d9d4f     Document Type: Review

References (51)

1. Williams DR, Cowey M, Tuck K, Day B. Psychogenic propriospinal myoclonus. Mov Disord 2008; 23:1312-1313.
2. Marsden CD, Hallett M, Fahn S. The nosology and pathophysiology of myoclonus. In: Marsden CD, Fahn S, editors. Movement disorders. London: Butterworths; 1982. pp. 196-248.
3. Chang VC, Frucht SJ. Myoclonus. Curr Treat Options Neurol 2008; 10:222-229.
4. Kinugawa K, Vidailhet M, Clot F, et al. Myoclonus-dystonia: an update. Mov Disord 2009; 24:479-489.
5. Koukouni V, Valente EM, Cordivari C, et al. Unusual familial presentation of epsilon-sarcoglycan gene mutation with falls and writer's cramp. Mov Disord 2008; 23:1913-1915.
6. Hess CW, Raymond D, Aguiar Pde C, et al. Myoclonus-dystonia, obsessive-compulsive disorder, and alcohol dependence in SGCE mutation carriers. Neurology 2007; 68:522-524.
7. Nardocci N, Zorzi G, Barzaghi C, et al. Myoclonus-dystonia syndrome: clinical presentation, disease course, and genetic features in 11 families. Mov Disord 2008; 23:28-34.
8. Roze E, Apartis E, Clot F, et al. Myoclonus-dystonia: clinical and electrophysiologic pattern related to SGCE mutations. Neurology 2008; 70:1010-1016.
9. Li JY, Cunic DI, Paradiso G, et al. Electrophysiological features of myoclonusdystonia. Mov Disord 2008; 23:2055-2061.
10. van der Salm SM, van Rootselaar AF, Foncke EM, et al. Normal cortical excitability in myoclonus-dystonia: a TMS study. Exp Neurol 2009; 216:300-305.
11. Meunier S, Lourenco G, Roze E, et al. Cortical excitability in DYT-11 positive myoclonus dystonia. Mov Disord 2008; 23:761-764.
12. Foncke EM, Bour LJ, Speelman JD, et al. Local field potentials and oscillatory activity of the internal globus pallidus in myoclonus-dystonia. Mov Disord 2007; 22:369-376.
13. Luciano MS, Ozelius L, Sims K, et al. Responsiveness to levodopa in epsilon-sarcoglycan deletions. Mov Disord 2009; 24:425-428.
14. Frucht SJ, Bordelon Y, Houghton WH, Reardan D. A pilot tolerability and efficacy trial of sodium oxybate in ethanol-responsive movement disorders. Mov Disord 2005; 20:1330-1337.
15. Cif L, Valente EM, Hemm S, et al. Deep brain stimulation in myoclonusdystonia syndrome. Mov Disord 2004; 19:724-727.
16. Magarinos-Ascone CM, Regidor I, Martinez-Castrillo JC, et al. Pallidal stimulation relieves myoclonus-dystonia syndrome. J Neurol Neurosurg Psychiatry 2005; 76:989-991.
17. Kuncel AM, Turner DA, Ozelius LJ, et al. Myoclonus and tremor response to thalamic deep brain stimulation parameters in a patient with inherited myoclonus-dystonia syndrome. Clin Neurol Neurosurg 2009; 111:303-306.
18. Trottenberg T, Meissner W, Kabus C, et al. Neurostimulation of the ventral intermediate thalamic nucleus in inherited myoclonus-dystonia syndrome. Mov Disord 2001; 16:769-771.
19. McKeon A, Pittock SJ, Glass GA, et al. Whole-body tremulousness: isolated generalized polymyoclonus. Arch Neurol 2007; 64:1318-1322.
20. Caviness JN. Myoclonus. Parkinsonism Relat Disord 2007; 13 (Suppl 3): 375-384.
21. Asconapé J, Diedrich A, DellaBadia J. Myoclonus associated with the use of gabapentin. Epilepsia 2000; 41:479-481.
22. Holtkamp M, Halle A, Meierkord H, Masuhr F. Gabapentin-induced severe myoclonus in a patient with impaired renal function. J Neurol 2006; 253:382-383.
23. Ege F, Koçak Y, Titiz AP, et al. Gabapentin-induced myoclonus: case report. Mov Disord 2008; 23:1947-1948.
24. Huppertz HJ, Feuerstein TJ, Schulze-Bonhage A. Myoclonus inepilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia 2001; 42:790-792.
25. Hellwig S, Amtage F. Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain. Epilepsy Behav 2008; 13:418-420.
26. K̈lviäinen R, Khyuppenen J, Koskenkorva P, et al. Clinical picture of EPM1-Unverricht-Lundborg disease. Epilepsia 2008; 49:549-556.
27. Chew NK, Mir P, Edwards MJ, et al. The natural history of Unverricht-Lundborg disease: a report of eight genetically proven cases. Mov Disord 2008; 23:107-113.
28. Magaudda A, Ferlazzo E, Nguyen VH, Genton P. Unverricht-Lundborg disease, a condition with self-limited progression: long-term follow-up of 20 patients. Epilepsia 2006; 47:860-866.
29. Mascalchi M, Michelucci R, Cosottini M, et al. Brainstem involvement in Unverricht-Lundborg disease (EPM1): an MRI and (1)H MRS study. Neurology 2002; 58:1686-1689.
30. Korja M, Kaasinen V, Lamusuo S, et al. Substantial thalamostriatal dopaminergic defect in Unverricht-Lundborg disease. Epilepsia 2007; 48:1768-1773.
31. Delgado-Escueta AV, Enrile-Bacsal F. Juvenile myoclonic epilepsy of Janz. Neurology 1984; 34:285-294.
32. Martinez-Juarez IE, Alonso ME, Medina MT, et al. Juvenile myoclonic epilepsy subsyndromes: family studies and long-term follow-up. Brain 2006; 129: 1269-1280.
33. Baykan B, Altindag EA, Bebek N, et al. Myoclonic seizures subside in the fourth decade in juvenile myoclonic epilepsy. Neurology 2008; 70:2123-2129.
34. Medina MT, Suzuki T, Alonso ME, et al. Novel mutations in myoclonin1/EFHC1 in sporadic and familial juvenile myoclonic epilepsy. Neurology 2008; 70:2137-2144.
35. Pascalicchio TF, de Araujo Filho GM, da Silva Noffs MH, et al. Neuropsychological profile of patients with juvenile myoclonic epilepsy: a controlled study of 50 patients. Epilepsy Behav 2007; 10:263-267.
36. Piazzini A, Turner K, Vignoli A, et al. Frontal cognitive dysfunction in juvenile myoclonic epilepsy. Epilepsia 2008; 49:657-662.
37. Deppe M, Kellinghaus C, Duning T, et al. Nerve fiber impairment of anterior thalamocortical circuitry in juvenile myoclonic epilepsy. Neurology 2008; 71:1981-1985.
38. Kim JH, Lee JK, Koh SB, et al. Regional grey matter abnormalities in juvenile myoclonic epilepsy: a voxel-based morphometry study. Neuroimage 2007; 37:1132-1137.
39. Noachtar S, Andermann E, Meyvisch P, et al. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008; 70:607-616.
40. Sharpe DV, Patel AD, Abou-Khalil B, Fenichel GM. Levetiracetam monotherapy in juvenile myoclonic epilepsy. Seizure 2008; 17:64-68.
41. Striano P, Caranci F, Di Benedetto R, et al. (1)H-MR spectroscopy indicates prominent cerebellar dysfunction in benign adult familial myoclonic epilepsy. Epilepsia 2009; Nov 22 [Epub ahead of print].
42. Brown P. Abnormal oscillatory synchronisation in the motor system leads to impaired movement. Curr Opin Neurobiol 2007; 17:656-664.
43. Altindag E, Kara B, Baykan B, et al. MR spectroscopy findings in lafora disease. J Neuroimaging 2009; Nov 14 [Epub ahead of print].
44. Leu-Semenescu S, Roze E, Vidailhet M, et al. Myoclonus or tremor in orthostatism: an under-recognized cause of unsteadiness in Parkinson's disease. Mov Disord 2007; 22:2063-2069.
45. Glass GA, Ahlskog JE, Matsumoto JY. Orthostatic myoclonus: a contributor to gait decline in selected elderly. Neurology 2007; 68:1826-1830.
46. Alvarez M, Caviness JN. Primary progressive myoclonus of aging. Mov Disord 2008; 23:1658-1664.
47. Sharma P, Morgan JC, Sethi KD. Hiccups associated with dopamine agonists in Parkinson disease. Neurology 2006; 66:774.
48. Lester J, Raina GB, Uribe-Roca C, Micheli F. Hiccup secondary to dopamine agonists in Parkinson's Disease. Mov Disord 2007; 22:1667-1668.
49. Gerschlager W, Bloem B. Hiccups associated with levodopa in Parkinson's disease. Mov Disord 2009; 24:621-622.
50. Munts AG, Van Rootselaar AF, Van Der Meer JN, et al. Clinical and neuro-physiological characterization of myoclonus in complex regional pain syndrome. Mov Disord 2008; 23:581-587.
51. Lang AE, Angel M, Bhatia K, et al. Myoclonus in complex regional pain syndrome. Mov Disord 2009; 24:314-316.